A new standard combination for recurrent ovarian cancer?

Ovarian cancer that recurs more than 6 months following primary chemotherapy can respond to many different drugs, but retreatment with a combination of carboplatin and paclitaxel has become a standard of care. A combination of pegylated liposomal doxorubicin and carboplatin may provide a slightly, but significantly, greater therapeutic index than carboplatin and paclitaxel.